Every 8-K that The Pennant Group, Inc. (PNTG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PNTG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PNTG filings page.
The Pennant Group, Inc. reported strong second-quarter 2026 results, with total revenue of $298.0 million, up 35.8% year over year. Net income was $9.1 million, and GAAP diluted EPS was $0.25, while adjusted diluted EPS was $0.36.
Home health and hospice revenue rose to $237.8 million, up 43.2%, driven by total home health admissions of 28,947, up 62.3%, and hospice average daily census of 5,477, up 40.1%. Senior living revenue increased to $60.2 million, up 12.6%, supported by slightly higher occupancy and higher average monthly revenue per occupied unit.
Consolidated Adjusted EBITDA reached $24.3 million, up 48.2%, and Consolidated Adjusted EBITDAR was $37.6 million, up 33.3%. Management raised full-year 2026 guidance to revenue of $1,171.1–$1,190.1 million, adjusted diluted EPS of $1.34–$1.41, and adjusted EBITDA of $94.4–$98.0 million, including contributions from recently acquired UnitedHealth and Amedisys assets.
The Pennant Group, Inc. held its Annual Meeting of Stockholders on May 14, 2026, with 30,486,574 common shares present out of 34,953,297 shares entitled to vote as of March 17, 2026. Stockholders elected three Class I directors to serve until the 2029 Annual Meeting. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. In an advisory vote, stockholders approved the compensation of the company’s named executive officers as disclosed in the proxy materials.
The Pennant Group, Inc. reported strong first quarter 2026 results, with revenue of $285.4 million, up 36.0% from the prior-year quarter. GAAP diluted earnings per share were $0.24, compared to $0.22 a year earlier, and adjusted diluted earnings per share were $0.32 versus $0.27.
Net income attributable to Pennant was $8.5 million, a 9.6% increase, while adjusted net income reached $11.5 million, up 19.8%. Consolidated Adjusted EBITDA rose to $21.7 million, a 32.6% increase. Home health and hospice revenue grew 43.3% to $229.1 million, and senior living revenue increased 12.6% to $56.3 million, supported by higher admissions, hospice census and steady senior living occupancy.
The Pennant Group reported strong fourth-quarter and full-year 2025 results, with total revenue of $947.7 million, up 36.3%, and GAAP diluted EPS of $0.84. Adjusted diluted EPS was $1.18, reflecting acquisitions and operating improvements.
Fourth-quarter revenue reached $289.3 million, up 53.2%, and GAAP diluted EPS was $0.24 with adjusted EPS of $0.34. Home health and hospice revenue grew 41.0% for the year, while senior living revenue rose 22.3%.
For 2026, management guides to revenue between $1,133.6 million and $1,171.8 million, adjusted diluted EPS of $1.26–$1.36, and adjusted EBITDA of $88.5–$94.1 million, incorporating contributions from recently acquired UnitedHealth and Amedisys assets.
The Pennant Group, Inc. filed Amendment No. 2 to an earlier current report to add detailed financial information for its completed acquisition of certain Amedisys and UnitedHealth subsidiaries that provide home health, hospice and palliative care services.
The update supplies audited abbreviated financial statements for the acquired Amedisys and UnitedHealth subsidiaries for the year ended December 31, 2024, and unaudited abbreviated financial statements for the six months ended June 30, 2025. It also includes unaudited pro forma condensed combined financial statements for The Pennant Group and the acquired businesses for the same periods.
The company emphasizes that the pro forma data, filed as Exhibit 99.5, are illustrative, prepared under SEC rules, and are not intended to represent actual historical results or to predict future performance following the transaction.
The Pennant Group (PNTG) entered a material financing amendment. On November 3, 2025, the company added an incremental Term Loan A of $100,000,000 under its Amended and Restated Credit Agreement with Truist Bank and additional lenders.
The new term loans bear the same interest rate and have the same maturity date as the company’s revolving facility. Pennant used the proceeds to refinance a portion of outstanding revolver borrowings and to pay related fees and expenses, effectively shifting debt from revolving to term while keeping pricing and maturity aligned.
The credit facility includes customary representations and covenants, including financial tests based on the Leverage Ratio and the Interest/Rent Coverage Ratio, and limits on additional indebtedness, liens, significant corporate changes, dispositions, and restricted payments. Standard events of default apply, including payment defaults, certain healthcare law violations, change in control, bankruptcy, and other operational covenants; if uncured, lenders may accelerate the debt.
The Pennant Group (PNTG) furnished an update on its third‑quarter performance. On November 5, 2025, the company issued a press release reporting financial results for the quarter ended September 30, 2025, and made the release available as Exhibit 99.1. The company also plans to post an updated investor presentation on its website for upcoming meetings. The information under Items 2.02 and 7.01, including Exhibit 99.1, was furnished and is not deemed filed or incorporated by reference except as specifically stated.
The Pennant Group, Inc. filed an amended current report to update a previously furnished press release. This 8-K/A modifies Item 7.01 of the original October 2, 2025 filing by replacing Exhibit 99.1 with an amended press release.
The updated Exhibit 99.1 is described as an amended press release dated October 2, 2025 announcing the closing of a transaction. No other items from the original report are changed, and the company clarifies that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for securities law purposes.
The Pennant Group, Inc. amended its previously announced purchase agreement with UnitedHealth Group and Amedisys to expand the scope of a planned acquisition of home health, hospice, and palliative care businesses. The amendment adds additional entities and assets to be acquired by Pennant’s subsidiaries, including Cornerstone Healthcare, Tensaw River Healthcare, Threemile River Healthcare, and Bashaw River Healthcare. As a result, the total purchase price has been increased from $102,484,000 to $146,531,160, reflecting the larger portfolio of operations to be acquired.
The Pennant Group, Inc. completed a cash acquisition of certain home health, hospice, and palliative care operations from subsidiaries of UnitedHealth Group and Amedisys on October 1, 2025. Through its subsidiaries Cornerstone Healthcare, Inc. and Tensaw River Healthcare LLC, Pennant acquired specified equity interests and assets related to these service providers for $146,531,160 in cash, subject to post‑closing adjustments. The company later issued a press release announcing the closing of this transaction.